size: | Price | Quantity | |
---|---|---|---|
5 mg | $40.00 | ||
25 mg | $150.00 |
MPEP HCl (219911-35-0) is a potent (IC50 = 36 nM for quisqualate-stimulated phosphoinositide hydrolysis) and selective (over mGlu1b, -2, -3, -4a, -6, -7b, and -8a) antagonist of the metabotropic glutamate receptor subtype 5 (mGlu5).1 It is a positive allosteric modulator of human mGlu4.2 MPEP inhibition of mGlu5 has been studied for the treatment of many CNS disorders including Parkinson’s3,4, Fragile X syndrome5, and addiction6.
References/Citations:
1) Gasparini et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective, and systemically active mGlu5 receptor antagonist; Neuropharmacology 38 1493
2) Mathiesen et al. (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4(hmGlu4) by SIB-1893 and MPEP; Br. J . Pharmacol. 138 1026
3) Morin et al. (2010) Effect of metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys; Neuropharmacology 58 981
4) Morin et al. (2013) MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates; Neuropharmacology 66 355
5) Michalon et al. (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice; Neuron 74 49
6) Mihov and Hasler (2016) Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window; Int. J. Neuropsychopharmacol. 19 pyw002
Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee
MPEP HCl (219911-35-0) is a potent (IC50 = 36 nM for quisqualate-stimulated phosphoinositide hydrolysis) and selective (over mGlu1b, -2, -3, -4a, -6, -7b, and -8a) antagonist of the metabotropic glutamate receptor subtype 5 (mGlu5).1 It is a positive allosteric modulator of human mGlu4.2 MPEP inhibition of mGlu5 has been studied for the treatment of many CNS disorders including Parkinson’s3,4, Fragile X syndrome5, and addiction6.
References/Citations:
1) Gasparini et al. (1999) 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective, and systemically active mGlu5 receptor antagonist; Neuropharmacology 38 1493
2) Mathiesen et al. (2003) Positive allosteric modulation of the human metabotropic glutamate receptor 4(hmGlu4) by SIB-1893 and MPEP; Br. J . Pharmacol. 138 1026
3) Morin et al. (2010) Effect of metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys; Neuropharmacology 58 981
4) Morin et al. (2013) MPEP, an mGlu5 receptor antagonist, reduces the development of L-DOPA-induced motor complications in de novo parkinsonian monkeys: biochemical correlates; Neuropharmacology 66 355
5) Michalon et al. (2012) Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice; Neuron 74 49
6) Mihov and Hasler (2016) Negative Allosteric Modulators of Metabotropic Glutamate Receptors Subtype 5 in Addiction: a Therapeutic Window; Int. J. Neuropsychopharmacol. 19 pyw002
Calculate the molar concentration, mass or volume in a solution.
Concentration × Volume × Molecular Weight = Mass
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.